Cover of Oncology for the Inquisitive Mind

Oncology for the Inquisitive Mind

Oncology for the Inquisitive Mind

By: Michael Fernando and Josh Hurwitz
Listen for free

Season's Savings | 0.99 €/month for 3 months

5.99 €/month thereafter - terms apply. Cancel monthly.
Summary
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.

Hosted on Acast. See acast.com/privacy for more information.

Michael Fernando and Josh Hurwitz
Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • 221. Making Metastatic Breast Cancer Count with Vicki Durston
    17 Nov 2026

    How many Australians are living with metastatic breast cancer? Until recently, nobody could tell you.


    This episode we’re joined by Vicki Durston, Director of Policy and Advocacy at Breast Cancer Network Australia (BCNA). Vicki started out as a nurse and has spent more than 30 years in health leadership. Her team produced Australia’s first national estimate of people living with metastatic breast cancer.


    BCNA is the peak national organisation for Australians affected by breast cancer. It began in 1998 with a few hundred women sharing information in their living rooms. It’s now a network of more than 250,000 people with lived experience, with a national Helpline and a strong voice in Parliament House.


    We talk about why counting matters, how a medicines access campaign actually gets won, and why your postcode still shapes your outcome. We also touch on BCNA’s Seat at the Table program and Vicki’s work with the ABC Global Alliance and the WHO.


    For more episodes, resources and blog posts, visit www.inquisitiveonc.com

    Please find us on Twitter @InquisitiveOnc!

    If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


    Art courtesy of Taryn Silver

    Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


    Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


    Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

    Hosted on Acast. See acast.com/privacy for more information.

    Show more Show less
    34 min
  • 220. Back to Basics - Central Nervous System Tumours
    8 Nov 2026

    This episode is about IDH-mutant glioma, a cancer that often hits people in their thirties and forties who may live for decades, which makes the long-term cost of treatment matter as much as the benefit. We’re looking at two trials, almost thirty years apart. RTOG 9402 opened in 1994 and asked whether adding PCV chemotherapy to radiotherapy did better than radiotherapy alone in anaplastic oligodendroglioma. INDIGO asked whether a daily tablet, the IDH inhibitor vorasidenib, could let patients with grade 2 disease put off radiotherapy and chemotherapy altogether. One asks whether more is better. The other asks whether we can safely wait. What did they find, and what do they mean for the patient in front of you on Monday? Let’s get into it.


    Studies Discussed in Today's Episode

    RTOG 9402

    INDIGO


    For more episodes, resources and blog posts, visit www.inquisitiveonc.com

    Please find us on Twitter @InquisitiveOnc!

    If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


    Art courtesy of Taryn Silver

    Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


    Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


    Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

    Hosted on Acast. See acast.com/privacy for more information.

    Show more Show less
    29 min
  • 219. Back to Basics - Cervical Cancer
    3 Nov 2026

    Cervical cancer is notoriously difficult to treat, but treatment like most cancers continue to improve. This week we discuss two pivotal immunotherapy (Keynote) trials.


    KEYNOTE-826 was the first trial to show that adding immunotherapy to first-line chemotherapy helps women whose cervical cancer has come back or spread. They lived longer, and five-year results confirm the benefit lasts. KEYNOTE-A18 then moved pembrolizumab earlier, adding it to chemoradiation for newly diagnosed, high-risk disease, when the aim is cure. At three years, 82.6% of women were alive, compared with 74.8% with chemoradiation alone. Together, the two trials have made immunotherapy part of standard care across the course of this disease.


    Studies Discussed in Today's Episode

    KEYNOTE-826

    KEYNOTE A18


    For more episodes, resources and blog posts, visit www.inquisitiveonc.com

    Please find us on Twitter @InquisitiveOnc!

    If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


    Art courtesy of Taryn Silver

    Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


    Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


    Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

    Hosted on Acast. See acast.com/privacy for more information.

    Show more Show less
    24 min
adbl_web_anon_alc_button_suppression_t1
No reviews yet